Skip to content

Short-Course Radiotherapy ( Octa-Shot ) and Cisplatin for Advanced Inoperable Head and Neck Cancer

Hypofractionated Radiotherapy using Octa-Shot Regimen with Concurrent Cisplatin in Inoperable Locally Advanced Head and Neck Cancer: A Prospective Study - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110777
Enrollment
40
Registered
2026-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: Hypofractionated accelerated chemoradiation, palliative chemoradiotherapy: 28 Gray delivered in 8 fractions, twice daily over 4 days at 3.5 Gray per fraction with concurrent cisplatin @

Sponsors

Department of Radiotherapy and Radiation Medicine Institute of Medical Sciences BHU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven squamous cell carcinoma of head and neck, 2. Locally advanced unresectable disease (Stage IVA and IVB) as per AJCC 8th edition staging, 3. Age between 18 and 75 years, 4. ECOG performance status 0 to 2 at enrollment, 5. Patients unsuitable for definitive curative treatment due to extent or bulk of disease and/or comorbidities, 6. Adequate hematological, renal, and hepatic function, 7. No prior radiotherapy to the head and neck region, 8. Written informed consent obtained prior to enrollment

Exclusion criteria

Exclusion criteria: 1. Evidence of distant metastases, Nasopharyngeal carcinoma, 2. Prior radiotherapy to head and neck region, 3. Pregnant or lactating females, 4. Severe renal dysfunction or contraindication to cisplatin, 5. Any serious medical illness that may compromise patient safety or interfere with assessment of study outcomes

Design outcomes

Primary

MeasureTime frame
1. To evaluate the degree of symptom palliation (pain, dysphagia, bleeding and airway-related symptoms) 2. To assess the acute toxicity profileTimepoint: At Baseline, 3 weeks after 1st cycle of CTRT, 3 weeks after 2nd cycle of CTRT, 3 months after completion of both cycles of CTRT

Secondary

MeasureTime frame
To assess tumor responseTimepoint: 3 months;To evaluate quality of life changesTimepoint: 3 months;To determine progression-free survival (PFS) and overall survival (OS)Timepoint: 3 months

Countries

India

Contacts

Public ContactSunil Choudhary

Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, BHU, Varanasi

drsunil104@gmail.com9559481453

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026